Pharma BD Deal Intelligence
Alkermes, Inc. / Cephalon, Inc. (Vivitrol rights)
2008 · Co-Development · $27M · Complete
Announcement Sentiment
71
Positive
Termination of Vivitrol JV; Alkermes regained full US commercialization rights; $11M from Cephalon (loss share) + $16M Alkermes manufacturing equipment buyback; ~$120M deferred revenue recognized
Key facts
- Announced Dec 01, 2008
- Deal value $27M
- Deal type Co-Development
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals